Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jan;39(1):125–131. doi: 10.1128/aac.39.1.125

Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS.

K K Van Rompay 1, M G Otsyula 1, M L Marthas 1, C J Miller 1, M B McChesney 1, N C Pedersen 1
PMCID: PMC162497  PMID: 7695293

Abstract

Simian immunodeficiency virus (SIV) infection of newborn rhesus macaques is a practical animal model of pediatric AIDS. Intravenous inoculation of rhesus newborns with uncloned SIVmac resulted in a high virus load, no antiviral immune responses, severe immunodeficiency, and a high mortality rate within 3 months. In contrast, immediate oral zidovudine (AZT) treatment of SIV-inoculated rhesus newborns either prevented infection or resulted in reduced virus load, enhanced antiviral immune responses, a low frequency of AZT-resistant virus isolates, and delayed disease progression with negligible toxicity. These results suggest that early chronic AZT treatment of human immunodeficiency virus-exposed newborns may have benefits that outweigh its potential side effects.

Full Text

The Full Text of this article is available as a PDF (238.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blanche S., Duliege A. M., Navarette M. S., Tardieu M., Debré M., Rouzioux C., Seldrup J., Kouzan S., Griscelli C. Low-dose zidovudine in children with an human immunodeficiency virus type 1 infection acquired in the perinatal period. Pediatrics. 1991 Aug;88(2):364–370. [PubMed] [Google Scholar]
  2. Blanche S., Rouzioux C., Moscato M. L., Veber F., Mayaux M. J., Jacomet C., Tricoire J., Deville A., Vial M., Firtion G. A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. HIV Infection in Newborns French Collaborative Study Group. N Engl J Med. 1989 Jun 22;320(25):1643–1648. doi: 10.1056/NEJM198906223202502. [DOI] [PubMed] [Google Scholar]
  3. Bohm R. P., Jr, Martin L. N., Davison-Fairburn B., Baskin G. B., Murphey-Corb M. Neonatal disease induced by SIV infection of the rhesus monkey (Macaca mulatta). AIDS Res Hum Retroviruses. 1993 Nov;9(11):1131–1137. doi: 10.1089/aid.1993.9.1131. [DOI] [PubMed] [Google Scholar]
  4. Borkowsky W., Krasinski K., Paul D., Holzman R., Moore T., Bebenroth D., Lawrence R., Chandwani S. Human immunodeficiency virus type 1 antigenemia in children. J Pediatr. 1989 Jun;114(6):940–945. doi: 10.1016/s0022-3476(89)80434-2. [DOI] [PubMed] [Google Scholar]
  5. Boucher F. D., Modlin J. F., Weller S., Ruff A., Mirochnick M., Pelton S., Wilfert C., McKinney R., Jr, Crain M. J., Elkins M. M. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr. 1993 Jan;122(1):137–144. doi: 10.1016/s0022-3476(05)83507-3. [DOI] [PubMed] [Google Scholar]
  6. Buseyne F., Blanche S., Schmitt D., Griscelli C., Rivière Y. Detection of HIV-specific cell-mediated cytotoxicity in the peripheral blood from infected children. J Immunol. 1993 Apr 15;150(8 Pt 1):3569–3581. [PubMed] [Google Scholar]
  7. Connor E. M., Sperling R. S., Gelber R., Kiselev P., Scott G., O'Sullivan M. J., VanDyke R., Bey M., Shearer W., Jacobson R. L. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994 Nov 3;331(18):1173–1180. doi: 10.1056/NEJM199411033311801. [DOI] [PubMed] [Google Scholar]
  8. Desrosiers R. C. The simian immunodeficiency viruses. Annu Rev Immunol. 1990;8:557–578. doi: 10.1146/annurev.iy.08.040190.003013. [DOI] [PubMed] [Google Scholar]
  9. Epstein L. G., Boucher C. A., Morrison S. H., Connor E. M., Oleske J. M., Lange J. M., van der Noordaa J., Bakker M., Dekker J., Scherpbier H. Persistent human immunodeficiency virus type 1 antigenemia in children correlates with disease progression. Pediatrics. 1988 Dec;82(6):919–924. [PubMed] [Google Scholar]
  10. Gabiano C., Tovo P. A., de Martino M., Galli L., Giaquinto C., Loy A., Schoeller M. C., Giovannini M., Ferranti G., Rancilio L. Mother-to-child transmission of human immunodeficiency virus type 1: risk of infection and correlates of transmission. Pediatrics. 1992 Sep;90(3):369–374. [PubMed] [Google Scholar]
  11. Husson R. N., Shirasaka T., Butler K. M., Pizzo P. A., Mitsuya H. High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy. J Pediatr. 1993 Jul;123(1):9–16. doi: 10.1016/s0022-3476(05)81530-6. [DOI] [PubMed] [Google Scholar]
  12. Japour A. J., Mayers D. L., Johnson V. A., Kuritzkes D. R., Beckett L. A., Arduino J. M., Lane J., Black R. J., Reichelderfer P. S., D'Aquila R. T. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother. 1993 May;37(5):1095–1101. doi: 10.1128/aac.37.5.1095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kellam P., Boucher C. A., Larder B. A. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1934–1938. doi: 10.1073/pnas.89.5.1934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kestler H., Kodama T., Ringler D., Marthas M., Pedersen N., Lackner A., Regier D., Sehgal P., Daniel M., King N. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science. 1990 Jun 1;248(4959):1109–1112. doi: 10.1126/science.2160735. [DOI] [PubMed] [Google Scholar]
  15. Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. doi: 10.1126/science.2467383. [DOI] [PubMed] [Google Scholar]
  16. Larder B. A., Kemp S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989 Dec 1;246(4934):1155–1158. doi: 10.1126/science.2479983. [DOI] [PubMed] [Google Scholar]
  17. Lohman B. L., Higgins J., Marthas M. L., Marx P. A., Pedersen N. C. Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay. J Clin Microbiol. 1991 Oct;29(10):2187–2192. doi: 10.1128/jcm.29.10.2187-2192.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lohman B. L., McChesney M. B., Miller C. J., McGowan E., Joye S. M., Van Rompay K. K., Reay E., Antipa L., Pedersen N. C., Marthas M. L. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol. 1994 Nov;68(11):7021–7029. doi: 10.1128/jvi.68.11.7021-7029.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lopez-Anaya A., Unadkat J. D., Schumann L. A., Smith A. L. Pharmacokinetics of zidovudine (azidothymidine). II. Development of metabolic and renal clearance pathways in the neonate. J Acquir Immune Defic Syndr. 1990;3(11):1052–1058. [PubMed] [Google Scholar]
  20. Luzuriaga K., Koup R. A., Pikora C. A., Brettler D. B., Sullivan J. L. Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children. J Pediatr. 1991 Aug;119(2):230–236. doi: 10.1016/s0022-3476(05)80732-2. [DOI] [PubMed] [Google Scholar]
  21. Luzuriaga K., McQuilken P., Alimenti A., Somasundaran M., Hesselton R., Sullivan J. L. Early viremia and immune responses in vertical human immunodeficiency virus type 1 infection. J Infect Dis. 1993 May;167(5):1008–1013. doi: 10.1093/infdis/167.5.1008. [DOI] [PubMed] [Google Scholar]
  22. McKinney R. E., Jr, Maha M. A., Connor E. M., Feinberg J., Scott G. B., Wulfsohn M., McIntosh K., Borkowsky W., Modlin J. F., Weintrub P. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. N Engl J Med. 1991 Apr 11;324(15):1018–1025. doi: 10.1056/NEJM199104113241503. [DOI] [PubMed] [Google Scholar]
  23. O'Sullivan M. J., Boyer P. J., Scott G. B., Parks W. P., Weller S., Blum M. R., Balsley J., Bryson Y. J. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol. 1993 May;168(5):1510–1516. doi: 10.1016/s0002-9378(11)90791-1. [DOI] [PubMed] [Google Scholar]
  24. Ochs H. D., Morton W. R., Tsai C. C., Thouless M. E., Zhu Q., Kuller L. D., Wu Y. P., Benveniste R. E. Maternal-fetal transmission of SIV in macaques: disseminated adenovirus infection in an offspring with congenital SIV infection. J Med Primatol. 1991 Jun;20(4):193–200. [PubMed] [Google Scholar]
  25. Para M. F. Use of zidovudine following occupational exposure to human immunodeficiency virus. Clin Infect Dis. 1992 Nov;15(5):884–885. doi: 10.1093/clind/15.5.884. [DOI] [PubMed] [Google Scholar]
  26. Pizzo P. A., Eddy J., Falloon J., Balis F. M., Murphy R. F., Moss H., Wolters P., Brouwers P., Jarosinski P., Rubin M. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988 Oct 6;319(14):889–896. doi: 10.1056/NEJM198810063191401. [DOI] [PubMed] [Google Scholar]
  27. Pollack H., Zhan M. X., Ilmet-Moore T., Ajuang-Simbiri K., Krasinski K., Borkowsky W. Ontogeny of anti-human immunodeficiency virus (HIV) antibody production in HIV-1-infected infants. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2340–2344. doi: 10.1073/pnas.90.6.2340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  29. Richman D. D., Grimes J. M., Lagakos S. W. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr. 1990;3(8):743–746. [PubMed] [Google Scholar]
  30. Richman D. D. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother. 1993 Jun;37(6):1207–1213. doi: 10.1128/aac.37.6.1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Saag M. S., Crain M. J., Decker W. D., Campbell-Hill S., Robinson S., Brown W. E., Leuther M., Whitley R. J., Hahn B. H., Shaw G. M. High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels. J Infect Dis. 1991 Jul;164(1):72–80. doi: 10.1093/infdis/164.1.72. [DOI] [PubMed] [Google Scholar]
  32. Scott G. B., Hutto C., Makuch R. W., Mastrucci M. T., O'Connor T., Mitchell C. D., Trapido E. J., Parks W. P. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med. 1989 Dec 28;321(26):1791–1796. doi: 10.1056/NEJM198912283212604. [DOI] [PubMed] [Google Scholar]
  33. Sutjipto S., Pedersen N. C., Miller C. J., Gardner M. B., Hanson C. V., Gettie A., Jennings M., Higgins J., Marx P. A. Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. J Virol. 1990 May;64(5):2290–2297. doi: 10.1128/jvi.64.5.2290-2297.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Tindall B., Carr A., Goldstein D., Penny R., Cooper D. A. Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune response. AIDS. 1993 Jan;7(1):127–128. doi: 10.1097/00002030-199301000-00020. [DOI] [PubMed] [Google Scholar]
  35. Van Rompay K. K., Marthas M. L., Ramos R. A., Mandell C. P., McGowan E. K., Joye S. M., Pedersen N. C. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection. Antimicrob Agents Chemother. 1992 Nov;36(11):2381–2386. doi: 10.1128/aac.36.11.2381. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES